ASCP 2021

Characterizing the Antipsychotic Activity and Safety Profile of the Novel Muscarinic Agonist KarXT (Xanomeline + Trospium): Primary and Secondary Results From a Phase 2 Placebo-Controlled Trial in Schizophrenia